Xiong Zou
Overview
Explore the profile of Xiong Zou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen S, Wang C, Zou X, Li H, Yang G, Su X, et al.
Front Genet
. 2024 Nov;
15:1450064.
PMID: 39600316
Background: Aging can impair the ability of elderly individuals to fight infections and trigger persistent systemic inflammation, a condition known as inflammaging. However, the mechanisms underlying the development of inflammaging...
2.
Zou X, Ding X, Feng Z, Ouyang Y, Li H, Wen K, et al.
Cell Rep Med
. 2024 Oct;
5(10):101779.
PMID: 39413735
Cisplatin is a cornerstone chemotherapy for nasopharyngeal carcinoma (NPC); however, certain patients are ineligible for cisplatin-based regimens. This phase 2 trial (NCT04405622) evaluated the efficacy and safety of gemcitabine and...
3.
Zou X, Feng Z, Hua Y, Liu Y, Xie Y, Ouyang Y, et al.
Head Neck
. 2023 Nov;
46(2):291-299.
PMID: 37974339
Objective: Endoscopic nasopharyngectomy (ENPG) with en bloc resection has been well accepted in resectable localized recurrent nasopharyngeal carcinoma (rNPC), but it is a difficult technique to master for most otorhinolaryngology...
4.
Chen S, Duan X, Li H, Peng L, Wang Z, Xu G, et al.
Cell Rep Med
. 2023 Nov;
4(11):101279.
PMID: 37951218
Locoregional radiotherapy added to chemotherapy has significantly improved survival in de novo metastatic nasopharyngeal carcinoma (mNPC). However, only 54% of de novo mNPC patients who received sequential chemoradiotherapy have complete...
5.
Chen X, Liao C, Zou X, Zhang B, Mo Z
Clin Transl Oncol
. 2023 Aug;
26(2):477-495.
PMID: 37594617
Objective: Due to the pivotal role cancer-associated fibroblasts (CAFs) play in tumor progression, our study aimed to develop a signature of CAFs-related gene (CRG) to predict the survival outcomes and...
6.
Yang Q, Zou X, Xie Y, Lin C, Ouyang Y, Liu Y, et al.
JAMA Netw Open
. 2023 Jul;
6(7):e2326127.
PMID: 37498596
Importance: Unlike substantial evidence in the prevention of chemotherapy-induced nausea and vomiting (CINV), research in the prevention of nausea and vomiting caused by concurrent chemoradiotherapy (CCRT) is currently lacking. Objective:...
7.
Ding X, Hua Y, Zou X, Chen X, Zhang X, Xu B, et al.
EClinicalMedicine
. 2023 Jul;
61:102043.
PMID: 37415845
Background: Treatment options for patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) are not clear after progression on previous treatment with PD-(L)1 inhibitor; critical gaps in evidence remain for such cases. Immunotherapy...
8.
Peng H, Huang Y, Wei G, Pang Y, Yuan H, Zou X, et al.
Biol Trace Elem Res
. 2023 Jun;
202(3):1084-1102.
PMID: 37382810
Aluminum contamination is a growing environmental and public health concern, and aluminum testicular toxicity has been reported in male rats; however, the underlying mechanisms of this toxicity are unclear. The...
9.
You R, Liu Y, Xie Y, Lin C, Duan C, Chen D, et al.
Lancet
. 2023 Feb;
401(10380):917-927.
PMID: 36842439
Background: Reirradiation in standard fractionation for locally advanced recurrent nasopharyngeal carcinoma after a previous course of high-dose radiotherapy is often associated with substantial late toxicity, negating its overall benefit. We...
10.
Lin M, Zhang X, You R, Liu Y, Cai H, Liu L, et al.
Nat Commun
. 2023 Feb;
14(1):610.
PMID: 36739462
It is critical to understand factors associated with nasopharyngeal carcinoma (NPC) metastasis. To track the evolutionary route of metastasis, here we perform an integrative genomic analysis of 163 matched blood...